Effects of the norepinephrine reuptake inhibitor reboxetine on the exploitation-exploration trade-off

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 48

Inclusion Criteria

Healthy volunteers between 18 and 25 years of age.
Volunteers are willing to give written informed consent to participate in the study and to comply with the study procedures.
Participants should speak Dutch fluently.
Normal or corrected-to-normal vision.

Exclusion Criteria

Clinically significant abnormal values for clinical chemistry, haematology or urinalysis at screening.
Clinically significant abnormal physical examination, vital signs or 12-lead ECG at screening.
Clinically significant (history of) psychiatric illness.
Clinically significant (history of) major internal or neurological illness.
Use of psychotropic medication.
Alcohol or substance abuse.
Pregnancy or breast feeding.
Positive urine screen for drugs of abuse.
Clinically significant acute illness within 7 days prior to study drug administration.
Clinically significant history of food and/or drug allergies.
Serology positive for hepatitis B surface antigen, hepatitis C antibodies or HIV antibodies.
Have received an experimental drug or used an experimental medical device within 90 days before the planned start of treatment.
Psychological and/or emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements.
Donation of 1 or more units (approximately 450 ml) of blood or acute blood loss of an equivalent amount of blood within 90 days before the planned treatment.
Exposure to any medication, including over-the-counter medication (not including paracetamol), within 2 weeks prior to treatment.
Subject not able to refrain from alcohol from 10 PM the night prior to the experimental session until end of the study day.
Subject not able to refrain from smoking from 10 PM the night prior to the experimental session until end of the study day.
Subject not able to refrain from xanthine intake from 10 PM the night prior to the experimental session until end of the study day.
Subject not able to refrain from grapefruit intake from 14 days prior to the experimental session until end of the study day.
Subject not able to refrain from heavy physical exertion from 24 hours prior to the experimental session until end of the study day.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are measures of performance on three cognitive tasks<br /><br>designed to examine exploitative and explorative behavior.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Pharmacodynamics:<br /><br>visual analogue scales (Bond & Lader)<br /><br>pupilsize<br /><br>adaptive tracking<br /><br>saccadic eye movements<br /><br>body sway<br /><br><br /><br>Pharmacokinetics:<br /><br>Cmax of reboxetine<br /><br>AUC (from zero to infinity) of reboxetine</p><br>